Atopic eczema

This long-term study is testing the safety and effectiveness of amlitelimab, an injected drug, in over 1600 people with moderate to severe atopic dermatitis (eczema) who have already taken part in earlier amlitelimab trials. Some participants will stop treatment temporarily to se…

This study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up open-labe…

This study tests a drug called lebrikizumab against a placebo in 221 adults and teenagers with moderate-to-severe hand and foot eczema. The treatment is given as an injection under the skin over 16 weeks. The main goal is to see if the drug can clear or nearly clear the skin rash…

This Phase 2 trial tests whether a stem cell therapy called ADSTEM can safely and effectively treat moderate-to-severe atopic dermatitis (eczema). About 118 adults with long-lasting eczema that hasn't responded well to standard creams will receive either ADSTEM stem cells or a pl…

This study looks at whether a daily pill called deucravacitinib can help people who have both moderate to severe psoriasis and eczema. About 50 adults will take the drug for 16 weeks while doctors track skin improvements and side effects. The goal is to find a treatment that work…

This early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixe…

This study tests an experimental drug called rezpegaldesleukin for adults with moderate-to-severe eczema (atopic dermatitis). About 396 participants will receive either the drug or a placebo for 16 weeks, and those who improve may continue treatment for up to a year. The goal is …

This study looks at the long-term safety of dupilumab (Dupixent) in children aged 6 months to 18 years with atopic dermatitis (eczema). About 880 kids who were in earlier dupilumab studies will continue treatment. Researchers will track side effects and check if a pre-filled pen …

This study tests a new drug, BBD-1, against standard steroids for IgA vasculitis, a disease that causes purple spots on the skin, joint pain, and can damage the kidneys. The trial will enroll 30 adults with confirmed IgA vasculitis. The goal is to see if BBD-1 can clear skin spot…

This Phase 2a study tests a new drug called GIA632 in 34 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it safely improves skin symptoms compared to a placebo. Participants are randomly assigned to receive either the drug or a placebo, and neithe…

This study tests a new drug called Afimkibart (RO7790121) in 160 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug improves eczema symptoms by at least 75% aft…

This study follows 262 people with moderate-to-severe atopic dermatitis (eczema) who received an injection of FURESTEM-AD in an earlier trial. Researchers are checking for long-term side effects and tracking how well the treatment controls eczema symptoms over time. The goal is t…

This study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a prior study will receive lebrikizumab for up to 116 weeks. The goal i…

This study looks at the long-term safety and tolerability of a drug called rocatinlimab for people with moderate-to-severe atopic dermatitis (eczema). It involves over 2,600 adults and teenagers who have already completed a previous rocatinlimab study. Researchers will monitor si…

This study tests an experimental drug called TRIV-509 in 95 adults with moderate to severe atopic dermatitis (eczema). Participants receive four doses of either TRIV-509 or a placebo, then switch to the other group. The goal is to see if TRIV-509 improves eczema symptoms and is s…

This study tests whether baricitinib, an oral anti-inflammatory drug, is safe and effective for children aged 2 to 17 with moderate to severe atopic dermatitis (eczema). About 516 participants will receive either baricitinib or a placebo, along with standard topical steroids. The…

This study is testing the long-term safety and effectiveness of a drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive injections of amlitelimab for up to 5 years, and researchers monitor for side effects an…

This study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. Part 1 looks at how well the drug improves skin symptoms over 24 weeks. Part 2 compares a new dosing schedule (every 12 weeks) to the current one (every 4 weeks) to see if it…

This study tests an experimental injection called TQH2722 in 500 adults with moderate to severe eczema (atopic dermatitis). The goal is to see if it can significantly reduce skin redness, itching, and rash compared to a placebo. Participants receive either the drug or a dummy sho…

This study tests whether a drug called amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. Participants who already responded to treatment in an earlier study will either continue the drug or receive a p…

This study looks at how well dupilumab (Dupixent) works over two years in about 48 children aged 6 to 14 with moderate-to-severe eczema. The main goal is to see if the drug improves the skin's barrier function, measured by water loss through the skin. All participants receive dup…

This study tests whether ATI-045 can safely reduce eczema symptoms like redness, itching, and skin patches in people with moderate-to-severe disease. About 110 adults who haven't had success with topical treatments will receive either the drug or a placebo. The main goal is to se…

This study tracks the safety and effectiveness of CIBINQO (abrocitinib) tablets in over 1,100 Japanese patients with atopic dermatitis (eczema) under real-world medical practice. Researchers will monitor side effects, treatment dropouts, and skin clearance over time. The goal is …

This study tests whether dupilumab, a drug already used for eczema and asthma, can help people with allergic contact dermatitis — a skin reaction to allergens like nickel or fragrances. Seventeen adults with confirmed allergies will receive the drug, and doctors will track change…

This study tests whether upadacitinib (Rinvoq), a daily pill already used in older patients, can safely improve moderate to severe eczema in children aged 2 to 11 in Japan. About 99 kids will receive either the drug or a placebo, plus a steroid cream, for up to a year. Researcher…

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard treatments. About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. …

This study tests a new drug called BAT6026 in 33 adults with moderate to severe atopic dermatitis (eczema) that hasn't responded well to topical treatments. The drug is a monoclonal antibody given as an injection. The goal is to see if it is safe and can reduce eczema severity by…

This study follows about 772 teenagers and adults with moderate to severe eczema who are taking upadacitinib (Rinvoq) as prescribed by their doctor. Researchers want to see how well the drug controls the disease over two years in everyday medical practice. Participants will have …

This study tests whether adding narrowband UVB phototherapy (a type of light treatment) to optimized topical therapy (creams, ointments, and skin care advice) helps adults with moderate atopic eczema more than topical therapy alone. About 316 adults whose eczema is not well contr…

This study tests a drug called lebrikizumab in children aged 6 months to 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either the drug or…

This study looks at how well methotrexate, a drug often used for arthritis, works for people with hand eczema. Researchers will track 50 patients to see if their skin improves and how their quality of life changes. The goal is to find better ways to manage this chronic skin condi…

This study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…

This study tests a new oral medication, jaktinib, for adults with moderate to severe atopic dermatitis (eczema). About 443 participants will receive either jaktinib or a placebo to see if it improves skin symptoms like redness and itching. The goal is to find a safe and effective…

This study tests whether a daily pill called upadacitinib, used with a steroid cream, can safely reduce eczema symptoms like itching and redness in teens and adults with moderate-to-severe disease. About 1,500 participants took the pill or a placebo for 16 weeks. The main goals w…

This early-stage trial tests the safety of a new drug called GB-7624 in 40 healthy adults. It is the first time this drug is being given to humans. The study gives single or multiple doses under the skin to see if it is safe and how the body processes it. If successful, it may ev…

This study was designed to see if dupilumab (Dupixent), an approved eczema drug, could improve growth and bone strength in children aged 6 to 12 with severe atopic dermatitis. It planned to enroll children whose eczema was not controlled by topical treatments. However, the study …

This phase 3 trial tests a drug called lebrikizumab, given as a shot, for people with moderate-to-severe eczema that hasn't improved with standard creams. Some participants also use a steroid cream. The study involves 301 adults and lasts about 62 weeks. Researchers are checking …

This study tests a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug is safe and helps clear skin. Participants receive the drug and are monitored for side effects and skin improvement over time.

This Phase 3 trial is testing an experimental oral drug called QY201 in 460 adults with moderate to severe atopic dermatitis (eczema). Participants will take either QY201 or a placebo daily for 16 weeks. The main goals are to see if the drug can significantly clear the skin and r…

This study looks at whether people with atopic dermatitis (eczema) that has been well-controlled for at least six months can safely take dupilumab less often. About 256 teens and adults will either stick with their usual every-two-week injection or gradually space out doses. The …

This Phase 3 trial tests an experimental injection called SHR-1819 in 652 adults with moderate to severe atopic dermatitis (eczema). Half get the drug, half get a placebo. The main goal is to see if it improves skin rash and itch after 16 weeks. If it works, it may offer a new wa…

This study tests whether giving pregnant women fish oil supplements can prevent asthma, eczema, and allergies in their children. 800 mothers took fish oil or a placebo from week 24 of pregnancy until one week after birth. The children are then followed for several years to see if…

This study tests whether using a special skin barrier cream (Epiceram) twice a day, along with a steroid cream at the first sign of eczema, can prevent food allergies in babies who develop eczema by 12 weeks old. The goal is to see if this proactive skin care reduces the number o…

This study tests a prescription cream called ruxolitinib for children and teens (ages 6 to 17) with moderate eczema. The cream is applied to the skin to reduce redness, itching, and rash. Researchers want to see if it works better than a cream with no medicine and check for side …

This early-stage trial tests a new ointment called CU-10101 in 64 people, first in healthy volunteers and then in those with mild to moderate atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug, with a preliminary look at whether it impr…

This study tests an experimental drug called SHR-1819 in 201 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it can significantly improve skin symptoms and reduce itching. Participants receive either the drug or a placebo, and researchers track sk…

This study tests whether ointments made from propolis, a natural substance from honeybees, can improve dry, itchy skin in adults with atopic tendencies. Thirty participants will apply either a propolis ointment or a plain base ointment twice daily for four weeks. Researchers will…

This early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored with clinic visi…

This study tests whether lebrikizumab can reduce itching and skin symptoms in people with moderate eczema who have a high itch burden. About 233 adults and teens will receive the drug for 24 weeks. The main goal is to see if at least 75% of skin symptoms improve or if itch scores…

This study tests a new medicine called EVO756 in 120 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it safely reduces skin redness, itching, and rash. The goal is to ease symptoms, not cure the condition.

This study tests whether a cream with 2% cholesterol can help repair the skin barrier and reduce symptoms in children aged 7-17 with mild to moderate eczema. Thirty participants will apply either the cholesterol cream or a placebo twice daily for 12 weeks. Researchers will measur…

This study looks at 600 hip or knee replacement patients to compare three different wound closure products: Sylke adhesive dressing, Exofin skin glue, and Suture Strip Plus. The goal is to see which method causes the fewest allergic skin reactions and gives the best scar appearan…

This study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…

This study tests an experimental drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it can reduce itching and improve skin condition compared to a placebo. About 131 participants will receive either a low dose, high dose,…

This early-stage study tests a new drug called ATTO1310 to see if it is safe and how the body processes it. It includes healthy adults, people with atopic dermatitis (eczema), and those with long-term itching. Participants receive either the drug or a placebo and are monitored fo…

This study tested whether Bodewell eczema products are safe and help improve skin symptoms in adults with atopic dermatitis (eczema). Fifteen participants used the products for 12 weeks. Researchers measured skin clearance and quality of life improvements.

This study tests a new injection called LP-003 in 6 teenagers aged 12 to 18 who have allergies like hay fever, asthma, or eczema. The main goal is to check if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and drug levels rat…

This early study will test a special microbubble bath system (Thera-Clean) on 20 people with certain skin diseases like epidermolysis bullosa, ichthyosis, atopic dermatitis, or psoriasis. The goal is to see if the chemical-free bubbles can clean wounds, reduce itching, and improv…

This study tests an experimental oral drug called HSK44459 in 150 adults with moderate-to-severe atopic dermatitis (eczema). Participants take the drug or a placebo twice daily for 12 weeks. The goal is to see if the drug safely reduces skin redness, swelling, and itch better tha…

This study follows up to 500 people with acute or chronic inflammatory disorders, such as infections or immune problems, over time. Researchers will monitor participants with standard tests and may screen them for other studies. The goal is to better understand these conditions a…

This study is observing how Elidel cream (pimecrolimus) is actually used in South and East Asian children aged 3 months to 12 years with mild to moderate atopic dermatitis (eczema). Researchers are tracking changes in eczema severity, itching, and sleep loss over the treatment pe…

This study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …

This study aims to understand how inflammation works in the skin and how certain anti-inflammatory drugs (biologics) affect it. Researchers will create small suction blisters on the skin of healthy volunteers and people with skin conditions, then analyze the fluid and cells. The …

This study looked at 81 adults with either palmoplantar psoriasis or palmoplantar eczema, two skin conditions that can look very similar on the palms and soles. Researchers used two special camera techniques—polarized dermoscopy and ultraviolet-induced fluorescence dermoscopy—to …

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This study enrolls 2500 pregnant women and follows their children from before birth up to age 3 (or 6 for those who continue). Researchers collect biosamples and environmental data to identify early-life markers and biological pathways that lead to food allergy and atopic dermati…

This study was designed to see how well JAK inhibitors work for adults with moderate-to-severe eczema in real-world settings. It planned to track skin improvement, itching, sleep, and side effects. However, the study was withdrawn before enrolling any participants, so no results …

This study follows 456 mothers and their children for 5 years to see if certain chemicals in the mother's blood during pregnancy are linked to the child developing eczema. Researchers will check children's skin regularly and track any eczema diagnosis. The goal is to understand p…

This study looks at how bacteria living on the skin influence inflammation and skin barrier damage in people with eczema or other skin diseases. Researchers will collect skin samples and measure things like moisture loss, eczema severity, and quality of life in 100 participants. …

This study looks at skin and blood samples from 505 children with eczema (atopic dermatitis) to find biological markers that explain the disease. Researchers compare these markers to those in adults to see if they are similar. The goal is to better understand what causes eczema i…

This early-stage study tests a new drug called SHR-1819 in 160 healthy adults to see how it enters the body when given with different injection devices. The goal is to compare the drug levels and safety between devices, not to treat any disease. Participants must be 18-55 years o…

This study aims to find specific gene changes (filaggrin mutations) in 300 Latinx adults with eczema. Researchers will use advanced DNA testing to see how these changes relate to the disease. The goal is to better understand eczema in this group, not to test a new treatment.

This study looks at whether tracking how often people use moisturizer can help treat dry skin caused by eczema. Thirty adults with dry skin will receive a moisturizer and be split into three groups: one with no extra help, one with weekly surveys, and one using a device to measur…

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study looks at blood inflammation in people with moderate to severe atopic dermatitis (eczema). Researchers will take blood samples before and after 3 months of treatment to see how immune signals change. The goal is to better understand the immune response in different pati…

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) who are starting treatment with dupilumab in Spain. Researchers will observe how the drug is used in everyday practice, its effectiveness, and any side effects over two years. No extr…

This registry will follow 10,000 adults with atopic dermatitis (eczema) who are already using approved treatments. Researchers will collect data on how well the treatments work and any side effects over time. The goal is to better understand the disease, its complications, and cu…

This early-stage study tests the safety of PF-08049820, a medicine being developed for eczema (atopic dermatitis), in about 71 healthy adults. Participants will take single or multiple doses of the drug or a placebo, and researchers will monitor how the body processes it and whet…

This study followed 221 breastfeeding mothers and their babies to see if small molecules called microRNAs in breast milk are linked to allergies, eczema, or wheezing in the first year of life. Researchers measured these molecules in milk samples and tracked babies' health. The go…

This study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…

This study follows 858 people aged 12 and older with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers will collect information on their medical history, skin symptoms, and quality of life over time to see how the medicine works in everyday practice…

This study aimed to learn more about the unpredictable swelling attacks in people with bradykinin-mediated angioedema, a rare condition that can cause life-threatening airway swelling. Participants would have used a smartphone app daily to report attacks and possible triggers. Th…

This study looks at how a new medicine (PF-08049820) is processed by the body when taken alone or with another drug (rabeprazole). It involves 18 healthy Chinese adults aged 18-65. Participants take both medicines by mouth, and blood samples are collected to measure drug levels. …

This study looks at how a new medicine called PF-08049820 changes the way birth control pills, a sedative, and a blood thinner move through the body. It involves 16 healthy adult women who will take the drugs alone and then with PF-08049820. The results will help plan future stud…

This study follows 8,000 children aged 2 to 17 with eczema who have used Elidel cream (pimecrolimus 1%). Over 10 years, researchers track how many develop cancer, especially lymphoma and thyroid cancer. The goal is to see if the cream raises cancer risk. No new treatment is given…